Ranibizumab and bevacizumab for AMD

New England Journal of Medicine

Volumn 365, Issue 23, 2011, Pages 2237-

  Cheung, C M Gemmy ^a   Wong, Tien Y ^b  

^a SINGAPORE NATIONAL EYE CENTRE   (Singapore)

^b SINGAPORE EYE RESEARCH INSTITUTE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB;

ASIAN; DRUG DEVELOPMENT; DRUG EFFICACY; DRUG RESPONSE; EUROPE; HUMAN; LETTER; POLYPOIDAL CHOROIDAL VASCULOPATHY; PREVALENCE; PRIORITY JOURNAL; RACE DIFFERENCE; RETINA MACULA AGE RELATED DEGENERATION; UNITED STATES;

EID: 83155182823     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1107895     Document Type: Letter

References (5)

1. The CATT Research Group. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011;364:1897-908.
2. Rosenfeld PJ. Bevacizumab versus ranibizumab for AMD. N Engl J Med 2011;364:1966-7.
3. Light DW. Global drug discovery: Europe is ahead. Health Aff (Millwood) 2009;28:w969-w977.
4. Laude A, Cackett PD, Vithana EN, et al. Polypoidal choroidal vasculopathy and neovascular age-related macular degeneration: same or different disease? Prog Retin Eye Res 2010;29:19-29.
5. Kawasaki R, Yasuda M, Song SJ, et al. The prevalence of agerelated macular degeneration in Asians: a systematic review and meta-analysis. Ophthalmology 2010;117:921-7.